AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$62.34
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | ABBV Avg Daily Volume: 7,077,900
Last Update: 05/05/16 - 4:04 PM EDT
Volume: 0
YTD Performance: 5.23%
Open: $0.00
Previous Close: $62.34
52 Week Range: $45.45 - $71.60
Oustanding Shares: 1,611,238,226
Market Cap: 99,026,701,370
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 9 9 9
Moderate Buy 1 1 1 1
Hold 3 3 2 2
Moderate Sell 0 0 0 0
Strong Sell 1 0 0 0
Mean Rec. 1.81 1.50 1.38 1.38
Latest Dividend: 0.57
Latest Dividend Yield: 3.71%
Dividend Ex-Date: 04/13/16
Price Earnings Ratio: 18.29
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
18.29 18.40 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
17.36% -2.38% 39.53%
GROWTH 12 Mo 3 Yr CAGR
Revenue 14.50 0.20 0.07
Net Income 190.00 0.00 -0.01
EPS 185.20 -0.10 -0.02
Earnings for ABBV:
EBITDA 8.37B
Revenue 22.86B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $1.20 $1.21 $4.79 $5.82
Number of Analysts 8 6 9 9
High Estimate $1.21 $1.30 $4.89 $6.10
Low Estimate $1.18 $1.14 $4.72 $5.64
Prior Year $1.08 $1.13 $4.29 $4.79
Growth Rate (Year over Year) 11.00% 6.93% 11.66% 21.46%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Real Money

 | May 4, 2016 | 1:53 PM EDT

Larry Robbins, Carson Block and John Khoury hold court at the 2106 Sohn Conference.

By

Carleton English

 | May 2, 2016 | 10:30 AM EDT

The interest areas of these investors span health care, hotels and international intrigue. Real Money takes a quick look at what they may discuss...

By

Jim Cramer

 | Apr 28, 2016 | 1:14 PM EDT

The M&A activity is an incredible and a welcome sign.

By

Bret Jensen

 | Apr 28, 2016 | 10:00 AM EDT

This earnings season continues to disappoint, and technology names are leading the downward charge.

By

Bret Jensen

 | Apr 22, 2016 | 9:00 AM EDT

There are lots of winners in the first quarter.

By

Bret Jensen

 | Apr 21, 2016 | 10:00 AM EDT

It's important to focus on hitting singles in this overbought and earnings-starved environment.

By

David Katz

 | Apr 20, 2016 | 7:00 AM EDT

Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.

By

Bret Jensen

 | Apr 19, 2016 | 10:00 AM EDT

This will still be fourth quarter in a row that profits have declined year over year.

By

Tony Owusu

 | Apr 12, 2016 | 8:22 AM EDT

U.S. indices look to reverse yesterday's losses as crude prices continue their climb. 

By

Bret Jensen

 | Apr 5, 2016 | 10:00 AM EDT

With low multiples and solid yields, these names look good for the long term.

$550 million to buy market on close.

breadth is weak and fear is rising in front NFP. we will add protection. BOUGHT SPY MAY 20...
Market has lost early but slight gains, and now sports small losses. Equities don't seem ...
Is to find Yale Liebowitz's photo (he was Pablo's best friend in first grade) in The Donal...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.